Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market ...

Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 ...

Bristol-Myers Squibb's key drugs are losing patent protection, while more recently launched drugs are struggling to meet peak ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15, ...

Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in ...

Bristol Myers Squibb's stock is down 35% from its 2022 highs as it faces patent cliffs. Pfizer is down 55% from its 2021 highs as it contends with similar challenges. If you like turnaround stories, ...

Bristol Myers Squibb & Co (NYSE:BMY) released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin ...